Standard solution for use in analysis of amino acids in plasma

Abstract

An external standard solution for use in the analysis of amino acid in plasma, containing, (1) at least one amino acid selected from the following components A, at a concentration of 0.0007 M to 0.49 M, and (2) (i) at least one amino acid selected from the following components B, at a concentration of 0.2 to 0.9 times of the lowest-concentration amino acid among the amino acids selected from components A, (ii) at least one amino acid selected from the following components C, at a concentration of 0.1 to 0.4 times of the lowest-concentration amino acid among amino acids selected from the components A, or (iii) at least one amino acid selected from the following components D, at a concentration of 0.05 to 0.2 times of the lowest-concentration amino acid among amino acids selected from the components A; [Components A] valine, glycine, alanine and glutamine [Components B] serine, proline, threonine, taurine, leucine, isoleucine, lysine, histidine, phenylalanine and tyrosine [Components C] asparagine, ornithine, arginine and tryptophan [Components D] glutamic acid, methionine, citrulline and cystine.

Claims

1. An internal standard solution comprising: proline, glycine, valine, methionine, tryptophan, tyrosine, and taurine, wherein one or more atoms of each amino acid is labeled with a stable isotope, and wherein proline has a lower concentration in the internal standard solution than glycine, valine, methionine, tryptophan, tyrosine, and taurine.

2. The internal standard solution according to claim 1, further comprising isoleucine, phenylalanine, and asparagine, wherein one or more atoms of each amino acid is labeled with a stable isotope, and wherein proline has a lower concentration in the internal standard solution than glycine, valine, methionine, tryptophan, tyrosine, taurine, isoleucine, phenylalanine, and asparagine.

3. The internal standard solution according to claim 2, further comprising ornithine, ethanolamine, glutamic acid, 3-methylhistidine, serine, histidine, and arginine, wherein one or more atoms of each amino acid is labeled with a stable isotope, and wherein proline has a lower concentration in the internal standard solution than glycine, valine, methionine, tryptophan, tyrosine, taurine, isoleucine, phenylalanine, asparagine, ornithine, ethanolamine, glutamic acid, 3-methylhistidine, serine, histidine, and arginine.

4. The internal standard solution according to claim 1, wherein proline has a lower concentration than all other amino acids in the internal standard solution.

5. The internal standard solution according to claim 1, wherein taurine has a higher concentration in the internal standard solution than proline, glycine, valine, methionine, tryptophan, and tyrosine.

6. An internal standard substance, wherein said internal standard substance is obtained by lyophilizing the internal standard solution of claim 1.

7. A method for analyzing amino acids in plasma, the method comprising (i) preparing an internal standard solution according to claim 1; (ii) adding the internal standard to a plasma sample; (iii) analyzing the amino acids and the internal standard in the plasma sample by separation analysis; and (iv) determining a concentration of the amino acids in the plasma sample based on results obtained from the internal standard.

8. The method of claim 7, wherein the separation analysis is conducted by liquid chromatography-mass spectrometry.

9. An internal standard solution comprising: proline, glycine, valine, methionine, tryptophan, tyrosine, and taurine, wherein one or more atoms of each amino acid is labeled with a stable isotope, and wherein taurine has a higher concentration in the internal standard solution than proline, glycine, valine, methionine, tryptophan, and tyrosine.

10. The internal standard solution according to claim 9, further comprising isoleucine, phenylalanine, and asparagine, wherein one or more atoms of each amino acid is labeled with a stable isotope, and wherein taurine has a higher concentration in the internal standard solution than proline, glycine, valine, methionine, tryptophan, tyrosine, isoleucine, phenylalanine, and asparagine.

11. The internal standard solution according to claim 10, further comprising omithine, ethanolamine, glutamic acid, 3-methylhistidine, serine, histidine, and arginine, wherein one or more atoms of each amino acid is labeled with a stable isotope, and wherein taurine has a higher concentration in the internal standard solution than proline, glycine, valine, methionine, tryptophan, tyrosine, isoleucine, phenylalanine, asparagine, ornithine, ethanolamine, glutamic acid, 3-methylhistidine, serine, histidine, and arginine.

12. The internal standard solution according to claim 9, wherein taurine has a higher concentration than all other amino acids in the internal standard solution.

13. An internal standard substance, wherein said internal standard substance is obtained by lyophilizing the internal standard solution of claim 9.

14. A method for analyzing amino acids in plasma, the method comprising (i) preparing an internal standard solution according to claim 9; (ii) adding the internal standard to a plasma sample; (iii) analyzing the amino acids and the internal standard in the plasma sample by separation analysis; and (iv) determining a concentration of the amino acids in the plasma sample based on results obtained from the internal standard.

15. The method of claim 14, wherein the separation analysis is conducted by liquid chromatography-mass spectrometry.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The FIGURE is a graph showing mean concentration, maximum concentration, minimum concentration, mean concentration +2 SD (standard deviation) and mean concentration 2 SD (standard deviation) of various kinds of amino acid which were determined in Example 1, concentration distributions of the external standard solution of the present invention (concentration 1 and concentration 5) which were prepared in Example 1, and the conventional mixed amino acids standard solution (concentration 1 and concentration 5) prepared in Comparative Example 1.

EMBODIMENTS FOR CARRYING OUT THE INVENTION

The External Standard Solution for Use in the Analysis of Amino Acid in Plasma of the Present Invention (The External Standard Solution of the Present Invention)

(2) The external standard solution of the present invention is the one which is employed in a quantitative analysis method using calibration curve method, and used for so called external standard, specifically, it is a mixed solution which was prepared by mixing plural amino acid products (commercial products) as a standard substance (criteria) in accordance with the ratio of existence concentration of various kinds of amino acid in a biological sample from human as a measuring object, and which is also referred to as an external mixed standard solution.

(3) The amino acid to be analyzed with the use of the external standard solution of the present invention includes, preferably, for example, valine (Val), glycine (Gly), alanine (Ala), glutamine (Glu), serine (Ser), proline (Pro), threonine (Thr), taurine (Tau), leucine (Ler), isoleucine (Ile), lysine (Lys), histidine (His), phenylalanine (Phe), tyrosine (Tyr), asparagine (Asn), ornithine (Orn), arginine (Arg), tryptophan (Trp), glutamic acid (Glu), methionine (Met), citrulline (Cit), cystine (Cys), -aminobutyric acid (ABA), ethanolamine (EtOHNH.sub.2), sarcosine (Sar), -aminobutyric acid (GABA), -aminoisobutiric acid (-AiBA), hydroxyproline (HyPro), aspartic acid (Asp), -aminoadipic acid (-AAA), hydroxylysine (HyLys), 1-methylhistidine (1MeHis), 3-methylhistidine (3MeHis), carnosine (Car), anserine (Ans), and so on; and, valine (Val), glycine (Gly), alanine (Ala), glutamine (Glu), serine (Ser), proline (Pro), threonine (Thr), taurine (Tau), leucine (Ler), isoleucine (Ile), lysine (Lys), histidine (His), phenylalanine (Phe), tyrosine (Tyr), asparagine (Asn), ornithine (Orn), arginine (Arg), tryptophan (Trp), glutamic acid (Glu), methionine (Met), citrulline (Cit), cystine (Cys), and so on are particularly preferable.

(4) The external standard solution of the present invention is the one which includes, although being selected appropriately from the above described amino acids depending on the amino acid to be measured, at least 1 amino acid to be included in the following components A, and at least 1 amino acid included in the following components B to D. Specifically, the one which includes at least 1 amino acid to be included in the components A, and at least 1 amino acid included in the components B is preferable, and the one which further includes at least 1 amino acid included in the components C is more preferable, and the one which further includes at least 1 amino acid included in the components D is further preferable.

(5) [Components A]

(6) valine, glycine, alanine and glutamine;

(7) [Components B]

(8) serine, proline, threonine, taurine, leucine, isoleucine, lysine, histidine, phenylalanine and tyrosine;

(9) [Components C]

(10) asparagine, ornithine, arginine and tryptophan;

(11) [Components D]

(12) glutamic acid, methionine, citrulline and cystine

(13) Among the above described components A, valine is preferable.

(14) Among the above described components B, serine, proline, threonine, leucine, isoleucine, lysine, histidine, phenylalanine and tyrosine are preferable, and leucine, isoleucine, histidine, phenylalanine and tyrosine are more preferable.

(15) Among the above described components C, tryptophan and asparagine are preferable, and tryptophan is more preferable.

(16) Among the above described components D, citrulline and methionine are preferable, and citrulline is more preferable.

(17) It should be noted that the external standard solution of the present invention may include, ethanolamine, sarcosine, -aminobutyric acid, -aminoisobutiric acid, hydroxyproline, aspartic acid, -aminoadipic acid, hydroxylysine, 1-methylhistidine, 3-methylhistidine, carnosine, anserine or -aminobutyric acid (hereinafter, abbreviated as components E) as the amino acids other than the above described components A to D.

(18) The components of the above described A to D are the ones classified according to the ratio of existence concentration of amino acids in human plasma, and in the order of components A, components B, components C and components D, the existence concentration of amino acid in human plasma decreases. This grouping was done according to the ratio of the existence concentration of amino acids in human plasma, more specifically, it was done not only according to the ratio of mean existence concentration, but (1) taking the median, the maximum value and the minimum value, etc. of existence concentration into consideration, the amino acid which the maximum value of existence concentration is high is set slightly higher side than the ratio of mean existence concentration, and the amino acid which the minimum value of existence concentration is low is set slightly lower side than the ratio of mean existence concentration, (2) taking the concentration distribution of amino acid into consideration, when the amino acid distributes mostly in higher concentration than the mean existence concentration, it is set slightly higher side than the ratio of mean existence concentration, and when the amino acid distributes mostly in lower concentration than the mean existence concentration, it is set slightly lower side than the ratio of mean existence concentration, or, (3) taking these multiple factors into consideration comprehensively, setting is made, etc. Specifically, for example, in the case of taurine, if it is simply classified according to the mean existence concentration, it will belong to group C, however, because the maximum value of the existence concentration is high, it is preferable to be set not to group C but to high concentration group B. In addition, in the case of isoleucine, if it is simply classified according to the mean existence concentration, it will belong to group C, however, according to the amino acid distribution, frequency of existence in higher concentration than the mean existence concentration is high, therefore, it is preferable to be set not to group C but to high concentration group B.

(19) It should be noted that the existence concentration of amino acid in human plasma may be determined based on the data obtained using many specimens, and the larger number of specimens create the higher accuracy, and therefore a preferable external standard solution which reflects more actual concentration in human plasma will be provided. The concentration ratio of amino acids in the external standard solution of the present invention is calculated using 6469 specimens, and is an excellent one having small standard error. It should be noted that, generally, when n pieces of sample is extracted from a population of standard deviation and element count N, the standard error of sample average is estimated by ((Nn)/(N1))*(/n), and when N is sufficiently large, estimation is done by /n. When concentration data are calculated from 6469 specimens, as compared, for example, with the case where the concentration data are calculated from 300 specimens, the standard error of sample average will be about 0.22 times, and it turns out that the data with smaller standard error can be obtained.

(20) Specific molar concentration ratio of the amino acid group of the above described components A to D, and preferred molar concentration will be shown as in the following table. It should be note that, in the table, with respect to the molar concentration ratio and the desirable molar concentration ratio when the group A is regarded as 1, in the case where number of the components A is one, it is the molar concentration ratio when the amino acid is regarded as 1; and in the case where the number of the components A is two or more, it represents the molar concentration ratio when the amino acid of the lowest concentration is regarded as 1. In addition, however, less than 1 time of group B of the components C represents that when the external standard solution of the present invention includes components B and the components B is one, it will be less than 1 time concentration of the amino acid concentration, when the components B is two or more, it will be less than 1 time concentration of the amino acid of the lowest concentration among them. The however, less than 1 time of group B, and besides less than 1 time of group C of the components D represents that when the external standard solution of the present invention includes components B and the components B is one, it will be less than 1 time concentration of the amino acid concentration, and when the components B is two or more, it will be less than 1 time concentration of the amino acid of the lowest concentration among them, and besides when the external standard solution of the present invention includes components C and the components C is one, it will be less than 1 time concentration of the amino acid concentration, and when the components C is two or more, it will be less than 1 time concentration of the amino acid of the lowest concentration among them.

(21) TABLE-US-00001 Preferable molar Molar concentration ratio when group concentration ratio when Group A is regarded as 1 group A is regarded as 1 A 1 1 B 0.2-0.9 0.4-0.9 C 0.1-0.4 Less than 0.2-0.4 However, less than 1 time of group B D 0.05-0.2 Less than 0.05-0.2 However, less than 1 time of group B, besides, less than 1 time of group C

(22) In addition, the concentration of the group A components in the external standard solution of the present invention is usually 0.0007 M to 0.49 M. As for the lower limit thereof, 0.0008 M or higher concentration that is higher than 767.7 M of glutamine which is the highest mean concentration +2 SD among group A components is preferable, and 0.0013 M or higher concentration that is higher than 1276.9 M of glutamine which is the highest concentration among group A components is more preferable. As for the upper limit, 0.1 M or less concentration is preferable, and 0.05 M or less concentration is more preferable. Group B to C may be set up so that the molar concentration ratio to group A will be within the ranges of the above described table.

(23) It should be noted that, in the case where the external standard solution of the present invention includes the above described components E, the concentration of the components E may be set up so that, when the external standard solution of the present invention includes components B, it is at less than 1 time concentration of the amino acid with the lowest concentration among them, and besides when the external standard solution of the present invention includes components C, it is at less than 1 time concentration of the amino acid with the lowest concentration among them, and besides, when the external standard solution of the present invention includes components D, it is at less than 1 time concentration of the amino acid with the lowest concentration among them.

(24) As for the external standard solution of the present invention, it is preferable not to make the components A and the components B coexisted with the components D or/and the components E during the time of storage. Specifically, for example, when the one which includes all components A to E is used as an external standard solution of the present invention, it is preferable to store them by dividing into components A, components B and components C, and components D and components E, and at the time of use, the external standard solution comprising all components A to E is prepared by mixing required amount, and then used.

(25) A specific example of preferable amino acid comprised in the external standard solution of the present invention includes, for example, the one which includes valine, and at least any one of leucine, isoleucine, phenylalanine, tyrosine, histidine, tryptophan, and citrulline. Among them, the one which includes valine, and at least any one of leucine and isoleucine is preferable; the one which includes valine, and at least any one of leucine and isoleucine, and at least any one of phenylalanine and tyrosine is more preferable; the one which includes valine, and at least any one of leucine and isoleucine, and at least any one of phenylalanine and tyrosine, and at least any one of histidine and tryptophan is further preferable; the one which includes valine, and at least any one of leucine and isoleucine, and at least any one of phenylalanine and tyrosine, and at least any one of histidine and tryptophan, and citrulline is particularly preferable.

(26) When amino acid is selected from valine, and at least any one of leucine, isoleucine, phenylalanine, tyrosine, histidine, tryptophan, and citrulline, and then an external standard solution are made, respective concentration ratio and desirable concentration ratio are as follows.

(27) TABLE-US-00002 Ratio of molar Preferable ratio of molar More preferable ratio of concentration when concentration when molar concentration when Amino acid valine is regarded as 1 valine is regarded as 1 valine is regarded as 1 Valine 1 1 1 Leucine 0.1-less than 1 0.2-0.9 0.4-0.9 Isoleucine 0.05-0.7 0.2-0.7 0.4-0.7 Phenylalanine 0.1-0.6 0.2-0.6 0.4-0.6 Tyrosine 0.1-0.7 0.2-0.7 0.4-0.7 Histidine 0.1-0.8 0.2-0.8 0.4-0.8 Tryptophan 0.1-0.6 0.1-0.4 0.2-less than 0.4 However, less than 1 However, less than 1 time of leucine, time of leucine, isoleucine, isoleucine, phenylalanine, phenylalanine, tyrosine, or tyrosine, or histidine histidine Citrulline 0.01-0.3 0.05-0.2 0.05-less than 0.2 However, when However, when leucine, isoleucine, leucine, isoleucine, phenylalanine, phenylalanine, tyrosine, histidine, tyrosine, histidine, or tryptophan is or tryptophan is included, less than 1 included, less than 1 time of them. time of them.

(28) In addition, when the external standard solution of the present invention is the one which includes at least valine, besides, includes at least any one of leucine, isoleucine, phenylalanine, tyrosine, histidine, tryptophan, and citrulline, concentration of valine is usually 0.0003 M to 0.49 M. As for the lower limit thereof, 0.0004 M or higher concentration that is higher than 341.4 M which is average concentration +2 SD of valine is preferable and 0.0005 M or higher concentration that is higher than 469.9 M which is a maximum concentration of valine is more preferable. As for the upper limit, 0.1 M or lower concentration is preferable, and 0.05 M or lower concentration is more preferable. With respect to other amino acids, the concentration ratios may be set up appropriately in the range used as above described amino acid ratios.

Preparation Method of the External Standard Solution of the Present Invention

(29) The external standard solution of the present invention may be prepared by dissolving the above described amino acids in water or buffer solution and the like so that it may provide the above described concentration ratio within the above described concentration range. Such buffer solution includes, specifically, for example, phosphate buffer solution, citrate buffer solution, borate buffer solution, Tris buffer solution such as Tris (hydroxymethyl)aminomethane buffer solution, Good's buffer solution such as N, N-bis (2-hydroxyethyl) glycine (Bicine) buffer solution, 2-[4-(2-hydroxyethyl)-1-pipperadinyl]ethane sulfonic acid (HEPES) buffer solution, 3-morpholinopropane sulfonic acid (MOPS) buffer solution, acetate buffer solution, and carbonate buffer solution, etc.

(30) The external standard solution of the present invention is prepared according to the actual amino acids concentration balance in human plasma samples, by preparing concentration ratio with each amino acid on the basis of a certain specified amino acid concentration. For example, it can be prepared based on the standard value of amino acid concentration shown in Table 3 of the following Example 1 which was obtained from 6469 specimens of human plasma by using conventional standard substance. Specifically, for example, using each amino acid, the external standard substance of 5 steps of concentration 1 to 5 as shown in the following Table 1 may be prepared. It should be noted that, although the concentration 3 is the most close to the average concentration in plasma in the concentrations 1 to 5 shown in the following Table 1, as an external standard solution of the present invention, it is desirable to provide only the concentration 1 of Table 1, and at the time of use, the concentration 2 to 5 of Table 1 is prepared by diluting appropriately this and used.

(31) TABLE-US-00003 TABLE 1 Amino acid Conc. 1 Conc. 2 Conc. 3 Conc. 4 Conc. 5 (Abbreviation) [M] [M] [M] [M] [M] Monoethanolamine 20 10 5 2 1 (EtOHNH.sub.2) Glycine (Gly) 1000 500 250 100 50 Sarcosine (Sar) 20 10 5 2 1 Alanine (Ala) 1000 500 250 100 50 -Aminobutyric acid 20 10 5 2 1 (GABA) -Aminoisobutiric acid 20 10 5 2 1 (-AiBA) -Aminobutyric acid 50 25 12.5 5 2.5 (-ABA) Serine (Ser) 500 250 125 50 25 Proline (Pro) 500 250 125 50 25 Valine (Val) 1000 500 250 100 50 Threonine (Thr) 500 250 125 50 25 Taurine (Tau) 500 250 125 50 25 Hydroxyproline (HyPro) 20 10 5 2 1 Leucine (Ler) 500 250 125 50 25 Isoleucine (Ile) 500 250 125 50 25 Asparagine (Asn) 250 125 62.5 25 12.5 Ornithine (Orn) 250 125 62.5 25 12.5 Aspartic acid (Asp) 20 10 5 2 1 Glutamine (Gln) 1000 500 250 100 50 Lysine (Lys) 500 250 125 50 25 Glutamic acid (Glu) 100 50 25 10 5 Methionine (Met) 100 50 25 10 5 Histidine (His) 500 250 125 50 25 -Aminoadipic acid 20 10 5 2 1 (-AAA) -Hydroxylysine 20 10 5 2 1 (-HyLys) Phenylalanine (Phe) 500 250 125 50 25 1-Methylhistidine 20 10 5 2 1 (1MeHis) 3-Methylhistidine 20 10 5 2 1 (3MeHis) Arginine (Arg) 250 125 62.5 25 12.5 Citrulline (Cit) 100 50 25 10 5 Tyrosine (Tyr) 500 250 125 50 25 Tryptophan (Trp) 250 125 62.5 25 12.5 Carnosine (Car) 20 10 5 2 1 Anserine (Ans) 20 10 5 2 1 Cystine (Cys.sub.2) 100 50 25 10 5

(32) In addition, in the preparation of the external standard solution of the present invention, as described in the clause of at the time of storage of the standard solution, it is preferable not to make the above described components A and components B coexist with components D or/and components E, and it is preferable to prepare as two separate amino acid mixed-solutions beforehand.

(33) Furthermore, it is more preferable to prepare a final external standard substance by mixing the two amino acid mixed-solutions (1 and 2) prepared beforehand and the amino acids with low stability in solution prepared at the time of use. That is, in another preferable embodiment of the present invention, the external standard substance solution of the present invention is preferable to be prepared as a kit which includes two amino acid mixed-solutions 1 and 2, and the amino acids for preparation at the time of use. In more detail, the amino acid mixed-solution 1 is the one which includes amino acids with relatively low existence concentration in plasma, and specific example of these amino acids are -AiBA, HyPro, Asp, -AAA, Sar, -HyLys, EtOHNH.sub.2, 3MeHis, 1MeHis, Ans, Car, GABA, -ABA, Cit, Cys.sub.2, Glu, and Met, etc. The amino acid mixed-solution 2 is the one which includes amino acids with relatively high existence concentration in plasma, and specific example of such amino acids are Arg, Orn, Ile, Leu, Phe, Pro, Ser, Thr, Tyr, Tau, His, Lys, Gly, Ala, and Val, etc. In addition, the amino acids for preparation at the time of use are the amino acids with relatively low stability in solution, and the specific examples are Asn, Gln, and Trp, etc.

(34) Therefore, the external standard substance of the present invention is prepared by mixing these reagents (that is, the amino acid mixed-solutions 1 and 2, and amino acids for preparation at the time of use). Composition of the prepared preferable external standard substance of the present invention is the one which includes, for example, each 0.02 M of Asp, 3MeHis, EtONH.sub.2, 1MeHis, HyPro, Sar, -AAA, -AiBA, -HyLys, GABA, Ans, Car, etc.; for example, 0.05 M of -ABA; each 0.1 M of Met, Cit, Glu, Cys.sub.2; for example, each 0.25 M of Trp, Orn, Asn, Arg, etc.; for example, each 0.50 M of Phe, Tyr, Tau, His, Ile, Ser, Leu, Thr, Pro, Lys, etc.; and for example, each 1.0 M of Val, Gly, Ala, Gln, etc.

The External Standard Substance for Use in the Analysis of Amino Acid in Plasma of the Present Invention

(35) The external standard substance of the present invention may be the one which is made by mixing various kinds of amino acid so as to provide the above described external standard solution of the present invention when a certain amount is dissolved in a certain volume of water or buffer solution, and said amino acids include the same one as described above in the section of external standard solution. In addition, as for said external standard substance, a lyophilized one of the external standard solution of the present invention, or the like is preferable.

The Internal Standard Solution for Use in the Analysis of Amino Acid in Plasma of the Present Invention

(36) The internal standard solution of the present invention is so-called internal standard which is used in the quantitative analytical method employing calibration curve method, specifically, taking the ratio of existence concentration of amino acids in a biological sample of measuring object and detection sensitivity, etc. into consideration, mainly, it is a solution obtained by preparing and mixing plural amino acids products as standard substance (criteria), and, it is also referred to as internal mixed standard solution.

(37) Although the internal standard solution of the present invention is characterized by including an amino acid labeled with one or more stable isotope, and it is preferable to be prepared according to the property of the amino acids in a biological sample. That is, for example, in consideration of existence concentration of amino acids, existence of contaminant components, detection sensitivity (detection sensitivity especially to a liquid chromatography-mass spectrometer), degree of peak overlapping between amino acid and internal standards substance, or two or more of these factors in a comprehensive manner, it is preferable to determine kinds of amino acid to be added to an internal standard substance, concentration of the internal standard substance, and the element to be labeled with a stable isotope. For example, with respect to proline which shows high detection sensitivity to the liquid chromatography-mass spectrometer, it is preferable to set the internal standard concentration lower as compared with human plasma balance amino acid concentration, and it is more preferable to make it the lowest concentration in the internal standard solution of the present invention. On the other hand, with respect to taurine which shows low detection sensitivity to the liquid chromatography-mass spectrometer and also has a susceptibility to contaminant components, and cystine which shows low detection sensitivity to the liquid chromatography-mass spectrometer and also shows unfavorable measurement stability due to split of a peak, it is preferable to set the internal standard concentration higher as compared with human plasma balance amino acid concentration, and it is more preferable to set the internal standard concentration of taurine the highest concentration in the internal standard solution of the present invention, and it is further preferable to make the internal standard concentration of taurine the highest concentration and to make the internal standard concentration of cystine high concentration next to taurine.

(38) The amino acid which is labeled with one or more of stable isotope in the internal standard solution of the present invention includes, proline, glycine, valine, methionine, tryptophan, tyrosine, taurine, isoleucine, phenylalanine, asparagine, ornithine, ethanolamine, glutamic acid, 3-methylhistidine, serine, histidine and arginine, sarcosine, alanine, -aminobutyric acid, -aminoisobutiric acid, -aminobutyric acid, threonine, hydroxyproline, leucine, aspartic acid, glutamine, lysine, -aminoadipic acid, -hydroxylysine, 1-methylhistidine, citrulline, carnosine, anserine, cystine, etc. Among them, the one which includes at least proline, glycine, valine, methionine, tryptophan, tyrosine, and taurine is preferable, and the one which includes at least proline, glycine, valine, methionine, tryptophan, tyrosine, taurine, isoleucine, phenylalanine, and asparagine is more preferable.

(39) The stables isotope in the internal standard solution of the present invention includes, for example, .sup.2H, .sup.13C, .sup.15N, and .sup.18O, etc., however, .sup.13C and .sup.15N, etc. are preferable.

(40) The amino acid which is labeled with one or more of stable isotope is preferable to have 3 or more of mass difference relative to unlabeled amino acid. By labeling to an unlabeled amino acid with stable isotope so as to bring about 3 or more of mass differences, the influence due to natural existence ratio of the isotope in the unlabeled object may be reduced, and highly precise analysis can be performed. For example, distribution of the natural isotopes in alanine (molecular formula; C.sub.3H.sub.7NO.sub.2, molecular mass 88) are molecular weight 88 (95.8%), 89 (3.74%), 90 (0.34%), and 91 (0.02%), and by making the mass difference into 3 or more, the influence of natural isotopes is avoided mostly.

(41) A specific example of the amino acid which has been labeled with one or more of stable isotopes includes, for example, Pro-U.sup.13C.sub.5, .sup.15N; Gly-U.sup.13C.sub.2, .sup.15N; Val-U.sup.13C.sub.5, .sup.15N; Met-U.sup.13C.sub.5, .sup.15N; Trp-U.sup.13C.sub.11, .sup.15N.sub.2; Tyr-Ring-.sup.13C.sub.6; Tau-U.sup.13C.sub.2; Ile-U.sup.13C.sub.6, .sup.15N; Phe-U.sup.13C.sub.9, .sup.15N; Asn-U.sup.13C.sub.4, .sup.15N.sub.2; Orn-U.sup.13C.sub.5; EtONH.sub.2-1, 1, 2, 2-d.sub.4; Glu-U.sup.13C.sub.5; 3MeHis-methyl-d.sub.3; Ser-U.sup.13C.sub.3, .sup.15N; His-U.sup.13C.sub.6, .sup.15N3; and Arg-U.sup.15N.sub.4.

(42) In the internal standard solution of the present invention, the concentration of the amino acid which has been labeled with one or more of stable isotopes is usually 10 to 300 M. With respect to the concentration of each amino acid, it is preferable for proline to be made lower concentration than any other amino acids, and it is more preferable for taurine to be made higher concentration than any other amino acids and besides proline is made to be lower concentration than any other amino acids. More specifically, it is preferable to set up the concentration lower in the order of taurine>ethanolamine, glutamic acid, 3-methylhistidine, serine, histidine, arginine, tyrosine>asparagine>isoleucine, ornithine, phenylalanine, tryptophan>glycine, valine, methionine>prorine.

Preparation Method of the Internal Standard Solution of the Present Invention

(43) The internal standard solution of the present invention, according to the property of the amino acids in a biological sample, is prepared by dissolving the above described amino acid which has been labeled with one or more stable isotopes in water or buffer solution and the like so that it may become the above described concentration range. Specifically, it can be prepared based on the standard value of amino acid concentration shown in Table 3 of the following Example. It should be noted that, the above described buffer solution includes the same one as described external standard solution of the present invention.

The Internal Standard Substance for Use in the Analysis of Amino Acid in Plasma of the Present Invention

(44) The internal standard substance of the present invention may be the one which is prepared by mixing various kinds of amino acid so as to provide the above described internal standard solution of the present invention when a certain amount is dissolved in a certain volume of water or buffer solution, and said amino acids include the same ones as described above in the section of internal standard solution. In addition, as for such internal standard substance, a lyophilized one of internal standard solution of the present invention or the like is preferable.

The Method for Quantitative Method of Amino Acid in Plasma of the Present Invention

(45) Generally, in the method of quantitative analysis using a calibration curve method, there are external standard method (that is, the method using the external standard solution or the external standard substance of the present invention) and internal standard method, and the like. In the quantitative method of the present invention, not only using external standard, if the standard substance which behave similarly to specimen in a specimen (that is, the internal standard solution or the internal standard substance of the present invention) is added to the specimen sample beforehand, it will become possible to increase accuracy of the quantitative method. That is, in the present invention, although it is possible to carry out only by the method using external standard solution or external standard substance, or only by the method using internal standard solution or internal standard substance, a quantitative analysis with more high accuracy can be achieved by employing in combination with both methods.

(46) The quantitative method of amino acid using the external standard solution or the external standard substance in the present invention may be carried out according to the calibration curve method well known per se, however, specifically, for example, 2-times diluted solution, 4-times diluted solution, 10-times diluted solution, and 20-times diluted solution of the external standard solution (or a solution of the external standard substance dissolved in water etc.) of the present invention are prepared, then undiluted solution and these diluted solutions are measured with an appropriate analytic method, and a calibration curve showing the relationship between peak area or peak height and concentration is made up. After that, for example, using human plasma, an amino acid of measuring object is determined, and the concentration is calculated by applying the obtained peak area or peak height to the above described calibration curve, and thus the quantitative method is carried out. The above described analysis method may be the analysis method usually employed in this field, and specifically, for example, liquid chromatography-mass spectrometry (LC-MS), liquid chromatography-mass spectrometry-mass spectrometry (LC-MS-MS), liquid chromatography-fluorescence analysis, liquid chromatography-UV detection, etc. are included, however, among them, LC-MS, LC-MS-MS, etc. using mass spectrometer are preferable. The condition of these analyses may be carried out according to the method well known per se.

(47) It should be noted that, since almost all amino acids have very weak absorption, fluorescence and electrochemical response, it is preferable to carry out analysis after labeling amino group of the amino acid, according to the analytical conditions. In this case, it is preferable to employ a labeling reagent which can exert high selectivity with higher sensitivity, and such labeling reagent includes, specifically, for example, the carbamate compounds described in the patent literature 1, among them, and a 3-aminopyridyl-N-hydroxysuccinimidyl carbamate (APDS) is preferable.

(48) The quantitative method of amino acid using the internal standard solution or the internal standard substance in the present invention may be carried out according to the method well known per se which uses internal standard, however, specifically, for example, the internal standard solution (or a solution of the internal standard substance dissolved in water etc.) is added to human plasma of a specimen, and using it, the amino acid of measuring object and the amino acid labeled with a stable isotope in the internal standard solution are measured by the method described in the quantitative method using the external standard solution, etc. From the obtained peak area or peak height of the amino acid of a measuring object and the peak area or peak height of the amino acid labeled with a stable isotope, the ratio is determined, and after correcting the error caused at the time of preparation and sample injection etc. based on the value, the concentration of the amino acid of a measuring object is calculated.

(49) Hereinafter, the present invention will be explained in more concrete by referring specific Examples, however, the scope of the present invention is not limited thereto in any way.

EXAMPLES

Experimental Example 1

Determination of Plasma Balance Amino Acid Concentration

(50) (1) Specimen

(51) As a specimen for determining plasma balance amino acid concentration, 6469 human plasma specimens were used.

(52) (2) External Standard Solution

(53) To commercially available Amino Acids Mixture Standard solution, Type H and Type B (produced by Wako Pure Chemical Industries, Ltd.), various kinds of amino acid listed in the following table were added so that it becomes such concentrations as listed in the following table, and 7 sorts of external standard solutions to add to the above described human plasma specimen were prepared. The concentration in the table shows the concentration after preparation.

(54) TABLE-US-00004 TABLE 2 External standard solution (M) Amino acid Conc. Conc. Conc. Conc. (Abbreviation) 1 2 3 4 Conc. 5 Conc. 6 Conc. 7 EtOHNH.sub.2 500 250 100 50 25 10 5 Gly 1000 500 250 100 50 20 10 Sar 125 62.5 25 12.5 6.25 2.5 1.25 Ala 1000 500 250 100 50 20 10 GABA 500 250 100 50 25 10 5 -AiBA 500 250 100 50 25 10 5 -ABA 500 250 100 50 25 10 5 Ser 500 250 100 50 25 10 5 Pro 500 250 100 50 25 10 5 Val 500 250 100 50 25 10 5 Thr 500 250 100 50 25 10 5 Tau 500 250 100 50 25 10 5 HyPro 500 250 100 50 25 10 5 Leu 500 250 100 50 25 10 5 Ile 500 250 100 50 25 10 5 Asn 500 250 100 50 25 10 5 Orn 500 250 100 50 25 10 5 Asp 500 250 100 50 25 10 5 Gln 1000 500 250 100 50 20 10 Lys 1000 500 250 100 50 20 10 Glu 500 250 100 50 25 10 5 Met 500 250 100 50 25 10 5 His 1000 500 250 100 50 20 10 -AAA 500 250 100 50 25 10 5 -HyLys 500 250 100 50 25 10 5 Phe 500 250 100 50 25 10 5 1MeHis 500 250 100 50 25 10 5 3MeHis 500 250 100 50 25 10 5 Arg 1000 500 250 100 50 20 10 Cit 500 250 100 50 25 10 5 Tyr 500 250 100 50 25 10 5 Trp 500 250 100 50 25 10 5 Car 500 250 100 50 25 10 5 Ans 500 250 100 50 25 10 5 Cys.sub.2 500 250 100 50 25 10 5
(3) Internal Standard Solution

(55) The following stable isotope-labeled amino acids were obtained from Ajinomoto Co., Inc., Cambridge Isotope Laboratories, Inc., Isotec, Inc., and the internal standard solution containing Gln-U.sup.13C.sub.5, .sup.15N.sub.2 (100 M), Arg-U.sup.15N.sub.4 (100 M), His-U.sup.15N.sub.3 (100 M) (a part is His-U.sup.13C.sub.6, .sup.15N.sub.3 (100 M)), Glu-U.sup.13C.sub.5, .sup.15N (200 M), Ser-U.sup.13C.sub.3, .sup.15N (100 M), Gly-2,2-d2.sub.2 (50 M), Ala-3,3,3-d.sub.3 (80 M), Leu-5,5,5-d.sub.3 (80 M), Lys-4,4,5,5-d.sub.4 (100 M), Val-2,3,4,4,4,5,5,5-d.sub.5 (25 M), Met-methyl-d.sub.3 (25 M), Pro-d.sub.7 (100 M), Trp-U.sup.13C.sub.11, .sup.15N.sub.2 (100 M), Phe-phenyl-d.sub.5 (100 M), Orn-U.sup.13C.sub.5 (80 M) and Cit-4,4,5,5-d.sub.4 (100 M) was prepared.

(56) (4) Pretreatment of Specimen

(57) After 50 L of the above described specimen was added to 50 L of the above described internal standard solution and mixed well, 100 L of acetonitrile was added and further mixed well. After carrying out centrifugal separation of said solution using a high-speed refrigerated micro-centrifugal separator, a supernatant fraction thereof was extracted.

(58) (5) Precolumn Derivatization

(59) Using the obtained supernatant fraction and a labeling reagent (3-aminopyridyl-N-hydroxysuccinimidyl carbamate reagent), precolumn derivatization was carried out. Specifically, to 12 L of 200 mM borate buffer solution (pH 8.8), 4 L of the supernatant fraction was added and mixed well, and further, 4 L of 3-aminopyridyl-N-hydroxysuccinimidyl carbamate reagent (the one which was prepared by dissolving 20 mg of the reagent in 1 mL of acetonitrile) was added and mixed well, then warmed at 55 C. for 5 minutes. Next, to said solution, 60 L of 25 mM formic acid aqueous ammonia solution (pH 6.0) and 20 L of 0.1% aqueous formic acid were added and mixed well, and used it as a sample for analysis of high performance liquid chromatography-mass spectrometry.

(60) (6) Analysis with High Performance Liquid Chromatography-Mass Spectrometry Aystem

(61) Analysis was carried out on the following conditions: High performance liquid chromatography: L-2100 series (Hitachi High-Technologies); Analytical column: Wakosil-II 3C8-100HG (Wako Pure Chemical Industries); Guard column: Wakosil-II 3C8-100HG (Wako Pure Chemical Industries); Mobile phases: Mobile phases A: 25 mM formic acid (pH was adjusted to 6.0 with aqueous ammonia); Mobile phases B: Acetonitrile/water (6:4 (v/v)); Column temperature: 40 C.; Sample injection volume: 5 L; Mass spectrometer: Thermo Scientific Surveyor MSQ Plus (Thermo Fisher Scientific); Monitor ion: EtONH.sub.2: 182, Gly: 196, Ala: 210, Sar: 210, GABA: 224, -AiBA: 224, -ABA: 224, Ser: 226, Pro: 236, Val: 238, Thr: 240, Tau: 246, HyPro: 252, Ile: 252, Leu: 252, Asn: 253, Asp: 254, Gln: 267, Glu: 268, Met: 270, His: 276, -AAA: 282, Phe: 286, 1MeHis: 290, 3MeHis: 290, Arg: 295, Cit: 296, Tyr: 302, Trp: 325, Car: 347, Ans: 361, Orn: 373, Lys: 387, -HyLys: 403, Cys.sub.2: 481
(7) Preparation of Calibration Curve

(62) As for the external standard solution, 5 points or more among 7 points of the concentrations 1 to 7 in Table 2 [the point which deviate from a range of 15% accuracy (lower limit was 20%) was excluded] was used, not passing the point of origin, but 1/x was used for weighting.

(63) From the above, the amino acid concentration (plasma balance amino acid concentrations) of 6469 specimens were calculated by applying the result of high performance liquid chromatography-mass spectrometry system to the calibration curve. The average concentration, the maximum concentration, the minimum concentration, and standard deviation thereof are shown in the following Table 3. In addition, the graph thereof is shown in the FIGURE.

(64) TABLE-US-00005 TABLE 3 Average Average conc. + conc. 2SD 2SD Average Maximum Minimum (Standard (Standard Amino acid conc. conc. conc. deviation) deviation) (Abbreviation) [M] [M] [M] [M] [M] EtOHNH.sub.2 7.2 21.6 2.0 10.6 3.7 Gly 235.7 714.1 97.3 350.9 120.5 Sar 1.8 9.3 0 4.1 0.4 Ala 374.7 881.7 122.6 548.3 201.1 GABA 0.1 4.5 0 0.6 0.5 -AiBA 1.7 89.0 0 5.3 1.9 -ABA 18.4 57.2 3.5 29.1 7.7 Ser 112.1 237.7 31.1 154.4 69.8 Pro 147.9 905.0 58.6 236.5 59.2 Val 245.6 469.9 90.3 341.4 149.7 Thr 106.5 278.4 41.0 154.6 58.5 Tau 52.1 375.4 15.7 87.5 16.6 HyPro 12.4 113.3 0 25.4 0.5 Leu 120.3 361.1 34.6 173.3 67.3 Ile 64.7 177.5 18.2 97.5 32.0 Asn 42.7 106.3 17.7 58.0 27.5 Orn 56.8 190.9 13.8 89.6 24.0 Asp 4.3 58.0 0 16.9 8.2 Gln 587.8 1276.9 223.6 767.7 407.9 Lys 207.1 426.4 83.6 283.9 130.4 Glu 35.5 133.8 0 69.8 1.2 Met 27.2 166.0 10.6 39.0 15.4 His 77.4 223.2 26.1 106.9 47.8 -AAA 0.2 24.5 0 2.2 1.8 -HyLys 0 11.2 0 0.4 0.4 Phe 63.7 157.0 29.3 87.0 40.4 1MeHis 5.1 100.7 0 17.4 7.2 3MeHis 5 43.4 0 8.8 1.3 Arg 95.4 226.3 27.2 139.4 51.3 Cit 21.4 94.0 6.7 34.0 8.7 Tyr 72.2 169.3 14.2 104.2 40.2 Trp 62.7 139.9 13.4 87.4 38.0 Car 0 3.7 0 0.5 0.4 Ans 0.1 4.2 0 0.8 0.7 Cys.sub.2 30.4 95.0 0 50.8 10.0

Example 1: Preparation of the External Standard Solution (a Solution Comprising Plasma Balance Amino Acids Mixed Substance) of the Present Invention

(65) Using various kinds of amino acid products (EtONH.sub.2, Gly, Sar, Ala, GABA, -AiBA, -ABA, Ser, Pro, Val, Thr, Tau, Hypro, Leu, Ile, Orn, Asp, Lys, Glu, Met, His, -AAA, -HyLys, Phe, 1MeHis, 3MeHis, Arg, Cit, Tyr, Car, Ans, and Cys.sub.2 were all produced by Wako Pure Chemical Industries, Ltd.), and by taking the amino acid concentration ratio in plasma [that is, human plasma balance amino acid concentration determined in Comparative Example 1 (refer to Table 3 and FIG. 1)] and the stability of the amino acid, into account, the following amino acid mixed solutions 1 and 2 were prepared.

(66) Amino Acid Mixed Solution 1:

(67) An aqueous solution containing each 200 M of -AiBA, HyPro, Asp, -AAA, Sar, -HyLys, EtONH.sub.2, 3MeHis, 1MeHis, Ans, Car and GABA; 500 M of -ABA; and each 1000 M of Cit, Cys.sub.2, Glu and Met.

(68) Amino Acid Mixed Solution 2:

(69) An aqueous solution comprising each 2500 M of Arg and Orn; each 5000 M of Ile, Leu, Phe, Pro, Ser, Thr, Tyr, Tau, His, and Lys; and each 10000 M of Gly, Ala, and Val.

(70) Subsequently, the amino acid mixed solutions 1 and 2, and Asn, Gln, and Trp (produced by SIGMA Co., Ltd.), which have been prepared at the time of use were mixed, and an external standard solution (plasma balance amino acids mixed standard solution), which amino acids was mixed with a composition shown below, was prepared.

(71) It includes each 20 M of Asp, 3MeHis, EtONH.sub.2, 1MeHis, HyPro, Sar, -AAA, -AiBA, -HyLys, GABA, Ans, and Car; 50 M of -ABA; each 100 M of Met, Cit, Glu, and Cys.sub.2; each 250 M of Trp, Orn, Asn, and Arg; each 500 M of Phe, Tyr, Tau, His, Ile, Ser, Leu, Thr, Pro, and Lys; and each 1000 M of Val, Gly, Ala, and Gln.

(72) The following Table 4 shows the contents of the external standard solution (plasma balance amino acids mixed standard solution) of the present invention prepared from the above described results. In addition, graphs about concentration 1 and concentration 5 are shown in the FIGURE.

Comparative Example 1: The External Standard Solution as a Conventional Product

(73) As a control for the external standard solution of the present invention in Example 1, an amino acids mixed standard solution was prepared using Amino Acids Mixture Standard solution, Type B (produced by Wako Pure Chemical Industries, Ltd.) and Amino Acids Mixture Standard solution, Type ANII (produced by Wako Pure Chemical Industries, Ltd.) in place of using the above described amino acids mixed solutions 1 and 2.

(74) In the following Table 4, the contents of said amino acids mixed standard solution is shown together with the above described external standard solution of the present invention. In addition, graphs for concentration V and concentration 5 are shown in the FIGURE.

(75) TABLE-US-00006 TABLE 4 Example 1 Comparative Example 1 External standard solution External standard solution (Plasma balance amino acids mixed standard (Conventional amino acids mixed standard Amino solution) solution) acid Conc. 1 Conc. 2 Conc. 3 Conc. 4 Conc. 5 Conc. 1 Conc. 2 Conc. 3 Conc. 4 Conc. 5 (Abbrev.) [M] [M] [M] [M] [M] [M] [M] [M] [M] [M] EtOHNH.sub.2 20 10 5 2 1 1000 500 250 100 50 Gly 1000 500 250 100 50 1000 500 250 100 50 Sar 20 10 5 2 1 2500 1250 625 250 125 Ala 1000 500 250 100 50 1000 500 250 100 50 GABA 20 10 5 2 1 1000 500 250 100 50 -AiBA 20 10 5 2 1 1000 500 250 100 50 -ABA 50 25 12.5 5 2.5 500 250 125 50 25 Ser 500 250 125 50 25 1000 500 250 100 50 Pro 500 250 125 50 25 1000 500 250 100 50 Val 1000 500 250 100 50 1000 500 250 100 50 Thr 500 250 125 50 25 1000 500 250 100 50 Tau 500 250 125 50 25 500 250 125 50 25 HyPro 20 10 5 2 1 1000 500 250 100 50 Leu 500 250 125 50 25 1000 500 250 100 50 Ile 500 250 125 50 25 1000 500 250 100 50 Asn 250 125 62.5 25 12.5 1000 500 250 100 50 Orn 250 125 62.5 25 12.5 1000 500 250 100 50 Asp 20 10 5 2 1 1000 500 250 100 50 Gln 1000 500 250 100 50 1000 500 250 100 50 Lys 500 250 125 50 25 1000 500 250 100 50 Glu 100 50 25 10 5 1000 500 250 100 50 Met 100 50 25 10 5 1000 500 250 100 50 His 500 250 125 50 25 1000 500 250 100 50 -AAA 20 10 5 2 1 500 250 125 50 25 -HyLys 20 10 5 2 1 1000 500 250 100 50 Phe 500 250 125 50 25 1000 500 250 100 50 1MeHis 20 10 5 2 1 1000 500 250 100 50 3MeHis 20 10 5 2 1 1000 500 250 100 50 Arg 250 125 62.5 25 12.5 1000 500 250 100 50 Cit 100 50 25 10 5 1000 500 250 100 50 Tyr 500 250 125 50 25 1000 500 250 100 50 Trp 250 125 62.5 25 12.5 1000 500 250 100 50 Car 20 10 5 2 1 1000 500 250 100 50 Ans 20 10 5 2 1 1000 500 250 100 50 Cys.sub.2 100 50 25 10 5 1000 500 250 100 50

Example 2: Preparation of the Internal Standard Solution of the Present Invention

(76) The following stable isotope-labeled amino acids were obtained from Ajinomoto Co., Inc., Cambridge Isotope Laboratories, Inc. and Isotec, Inc., and the internal standard solution containing Gln-U.sup.13C.sub.5, .sup.15N.sub.2 (100 M), Arg-U.sup.15N.sub.4 (100 M), His-U.sup.13C.sub.6, .sup.15N.sub.3 (100 M), Glu-U.sup.13C.sub.5, .sup.15N (100 M), Ser-U.sup.13C.sub.3, .sup.15N (100 M), Gly-U.sup.13C.sub.2, .sup.15N (50 M), Ala-3,3,3-d.sub.3 (100 M), Leu-5,5,5-d.sub.3 (80 M), Lys-U.sup.13C.sub.6, .sup.15N.sub.2 (130 M), Val-U.sup.13C.sub.5, .sup.15N (50 M), Met-U.sup.13C.sub.5, .sup.15N (50 M), Pro-U.sup.13C.sub.5, .sup.15N (25 M), Trp-U.sup.13C.sub.11, .sup.15N.sub.2 (80 M), Phe-U.sup.13C.sub.9, .sup.15N (80 M), Orn-U.sup.13C.sub.5 (80 M), Cit-4,4,5,5-d.sub.4 (100 M), Thr-U.sup.13C.sub.4 (100 M), Tyr-Ring-.sup.13C.sub.6 (100 M), Tau-U.sup.13C.sub.2 (250 M), Ile-U.sup.13C.sub.6, .sup.15N (80 M), Asn-U.sup.13C.sub.4, .sup.15N.sub.2 (90 M), 3MeHis-methyl-d.sub.3 (100 M), Asp-2,3,3-d.sub.3 (100 M), Cys2-3,3,3,3-d.sub.4 (200 M) and EtONH.sub.2-1,1,2,2-d.sub.4 (100 M) was prepared.

(77) As a control, the internal standard solution described in Non-patent Literature 4 was adjusted, and it was used as an internal standard solution (the conventional internal standard solution) as a comparative example for Example 2.

(78) The following table 5 shows the internal standard solutions for various kinds of amino acid when the concentration of various kinds of amino acid in human plasma are measured using the above described internal standard solution (the internal standard solution of the present invention) or the internal standard solution (the conventional internal standard solution) of Comparative Example. In the Table, gray colored frames indicate the amino acids for which the stable isotope of itself is not employed as the internal standard solution. As for the amino acids in gray colored frames, in consideration of the nearness of retention time with the amino acids which are not labeled with stables isotope, the physical properties of a compound, the result of an addition recovery examination, etc., the most suitable ones were selected from various kinds of amino acid which have been labeled with stable isotope.

(79) TABLE-US-00007 TABLE 5 Example 2 Internal Comparative Example standard solution Internal standard Amino (Internal standard solution (Conventional acid solution of the Conc. internal standard Conc. (Abbrev.) present invention) [M] solution) [M] EtOHNH.sub.2 EtONH.sub.2-1,1,2,2-d.sub.4 100 Gly Gly-U.sup.13C.sub.2,.sup.15N 50 Gly-2,2-d.sub.3 50 Sar* Glu-U.sup.13C.sub.5,.sup.15N 100 Ala Ala-3,3,3-d.sub.3 100 Ala-3,3,3-d.sub.3 80 GABA* 3MeHis-methyl-d.sub.3 100 -AiBA* EtONH2-1,1,2,2-d.sub.4 100 -ABA* 3MeHis-methyl-d.sub.3 100 Ser Ser-U.sup.13C.sub.3, .sup.15N 100 Ser-U.sup.13C.sub.3, .sup.15N 100 Pro Pro-U.sup.13C.sub.5, .sup.15N 25 Pro-d.sub.7 100 Val Val-U.sup.13C.sub.5, .sup.15N 50 Val-2,3,4,4,4,5,5,5-d.sub.8 25 Thr Thr-U.sup.13C.sub.4 100 Ser-U.sup.13C.sub.3, .sup.15N 100 Tau Tau-U.sup.13C.sub.4 100 Ala-3,3,3-d.sub.3 80 Hypro* Glu-U.sup.13C.sub.5, .sup.15N 100 Leu Leu-5,5,5-d.sub.3 80 Leu-5,5,5-d.sub.3 80 Ile Ile-U.sup.13C.sub.6, .sup.15N 80 Leu-5,5,5-d.sub.3 80 Asn Asn-U.sup.13C.sub.6, .sup.15N.sub.2 90 Ser-U.sup.13C.sub.3, .sup.15N 100 Orn Orn-U.sup.13C.sub.5 80 Lys-4,4,5,5-d.sub.4 100 Asp Asp-2,3,3-d.sub.3 100 Glu-U.sup.13C.sub.5, .sup.15N 200 Gln Gln-U.sup.13C.sub.5, .sup.15N.sub.2 100 Gln-U.sup.13C.sub.5, .sup.15N.sub.2 100 Lys Lys-U.sup.13C.sub.6, .sup.15N.sub.2 130 Lys-4,4,5,5-d4 100 Glu Glu-U.sup.13C.sub.5, .sup.15N 100 Glu-U.sup.13C.sub.5, .sup.15N 200 Met Met-U.sup.13C.sub.5, .sup.15N 50 Met-methyl-d.sub.3 25 His His-U.sup.13C.sub.6, .sup.15N.sub.3 100 His-U.sup.15N.sub.3 100 -AAA* Ser-U.sup.13C.sub.3, .sup.15N 100 -HyLys* Orn-U.sup.13C.sub.5 80 Phe Phe-U.sup.13C.sub.9, .sup.15N 80 Leu-5,5,5-d.sub.3 80 1MeHis* His-U.sup.13C.sub.6, .sup.15N.sub.3 100 3MeHis* 3MeHis-methyl-d.sub.3 100 Arg Arg-U.sup.15N.sub.4 100 Arg-U.sup.15N.sub.4 100 Cit Cit-4,4,5,5-d.sub.4 100 Pro-d.sub.7 100 Tyr Tyr-Ring-.sup.13C.sub.6 100 Pro-d.sub.7 100 Trp Trp-U.sup.13C.sub.11, .sup.15N.sub.2 80 Leu-5,5,5-d.sub.3 80 Car Arg-U.sup.15N.sub.4 100 Ans EtONH.sub.2-1,1,2,2-d.sub.4 100 Cys.sub.2 Cys.sub.2-3,3,3,3-d.sub.4 200

Example 3: Quantitative Analysis Using External Standard Solution of the Present Invention

(80) (1) Preparation of Biological Sample

(81) As a biological sample, the blood was collected from 5 healthy volunteers, and plasma was combined after plasma separation and used it as pooled plasma.

(82) (2) Preparation of Known Concentration Amino Acid Addition Plasma and Control Plasma

(83) A specimen which was prepared by mixing the obtained pool plasma with a mixed solution of known concentration amino acids described in the following Table 6 by 1:1 was used as known concentration amino acid addition plasma, and a specimen which was prepared by mixing the obtained pool plasma with waters by 1:1 was used as control plasma.

(84) (3) Pretreatment of Specimen

(85) To 50 L of the above described known concentration amino acid addition plasma or the control plasma, 50 L of the internal standard solution of Example 2 was added and mixed well, then 100 L of acetonitrile was added to it and mixed well.

(86) Subsequently, after carrying out centrifugal separation with a high-speed refrigerated micro-centrifugal separator, obtained supernatant fraction was used for analysis.

(87) (4) Precolumn Derivatization

(88) Using the obtained supernatant fraction and a labeling reagent (3-aminopyridyl-N-hydroxysuccinimidyl carbamate reagent), precolumn derivatization was carried out. Specifically, to 60 L of 200 mM borate buffer solution (pH 8.8), 20 L of the supernatant fraction was added and mixed well. Further, 20 L of 3-aminopyridyl-N-hydroxysuccinimidyl carbamate reagent (the one which was prepared by dissolving 20 mg of the reagent in 1 mL of acetonitrile) was added and mixed well, then warmed at 55 C. for 10 minutes. Subsequently, after said solution was kept standing to cool at room temperature, 100 L of 0.1% aqueous formic acid solution was added and mixed well, and used it as a sample for analysis of high performance liquid chromatography-mass spectrometry.

(89) (5) Analysis with High Performance Liquid Chromatography-Mass Spectrometry System

(90) Analysis was carried out on the following conditions: High performance liquid chromatography: 10Avp series (Shimazu Corporation); Analytical column: Inartsil C8-3 (GL Science Inc.); Guard column: Inartsil ODS-3 (GL Science Inc.); Mobile phases: Mobile phases A: 25 mM formic acid (pH was adjusted to 6.0 with aqueous ammonia); Mobile phases B: Acetonitrile/water (6:4 (v/v)); Column temperature: 40 C.; Sample injection volume: 3 L; Mass spectrometer: API3000 LC/MS/MS (AB SCIEX); Monitor ion (Q1/Q3): EtONH.sub.2: 182/121, Gly: 196/121, Ala: 210/121, Sar: 210/121, GABA: 224/121, -AiBA: 224/121, -ABA: 224/121, Ser: 226/121, Pro: 236/121, Val: 238/121, Thr: 240/121, Tau: 246/121, HyPro: 252/121, Ile: 252/121, Leu: 252/121, Asn: 253/121, Asp: 254/121, Gln: 267/121, Glu: 268/121, Met: 270/121, His: 276/121, -AAA: 282/121, Phe: 286/121, 1MeHis: 290/121, 3MeHis: 290/121, Arg: 295/121, Cit: 296/121, Tyr: 302/121, Trp: 325/121, Car: 347/121, Ans: 361/121, Orn: 373/121, Lys: 387/121, -HyLys: 403/121, Cys.sub.2: 481/121.
(6) Preparation of Calibration Curve

(91) Using the external standard solution of Example 1, as is the case with the above described known concentration amino acid addition plasma, derivatization treatment of the above described (4) was carried out, and analysis of (5) was performed. From the results of analysis, a calibration curve which has 20-times concentration difference between upper limit concentration and lower limit concentration was prepared. As for the external standard solution, 5 points of the concentration 1 to 5 in Table 4 (plasma balance amino acids mixed standard solutions) was used, not passing the point of origin, but 1/x was used for weighting.

(92) (7) Addition and Recovery of Amino Acid to Plasma

(93) From the measurement results of the known concentration amino acids addition plasma, addition and recovery rate was determined. The addition and recovery rate was calculated as follows:
Addition and recovery rate={(amino acid concentration in known concentration amino acids addition plasma)(amino acid concentration in control plasma)}2/added known concentration amino acid (%)

(94) It should be noted that each concentration was calculated after determining peak area ratio {(peak area of each component)/(peak area of internal standard solution)}, and using the above described calibration curve. The results are shown in Table 6. Here, the addition and recovery rate of Example is the value calculated based on the calibration curve which was made up using the external standard solution (plasma balance amino acid acids mixed standard solution) of Example 1.

Comparative Example 2: Quantitative Analysis Using the External Standard Solution of Comparative Example 1

(95) In (6) of Example 3, addition and recovery rate when the amino acids were added to human plasma was determined by the same method as Example 3 except for using 5 points of concentration 1 to 5 (conventional amino acids mixed standard solution) of Table 4. The results are shown in Table 6 in conjunction with the results of Example 3. In the Table, the addition and recovery rate of Comparative Example is the value calculated based on the calibration curve made up using the external standard solution (conventional amino acids mixed standard solution) prepared as a control.

(96) TABLE-US-00008 TABLE 6 Addition concentration Addition and recovery Amino (known concentration rate [%] acid amino acids mixed Comparative (Abbrev.) solution) [M] Example 3 Example 2 EtOHNH.sub.2 10 102% 35% Gly 500 106% 107% Sar 10 111% 0% Ala 500 98% 99% GABA 10 94% 0% -AiBA 10 102% 28% -ABA 25 105% 107% Ser 250 99% 87% Pro 250 100% 118% Val 500 100% 99% Thr 250 97% 84% Tau 250 98% 83% HyPro 10 102% 98% Leu 250 98% 96% Ile 250 101% 100% Asn 125 95% 92% Orn 125 102% 95% Asp 10 81% 48% Gln 1000 100% 97% Lys 250 103% 101% Glu 50 107% 108% Met 50 103% 109% His 250 93% 85% -AAA 10 101% 51% -HyLys 10 101% 392% Phe 250 102% 104% 1MeHis 10 95% 66% 3MeHis 10 100% 7% Arg 125 99% 91% Cit 50 103% 110% Tyr 250 97% 106% Trp 125 93% 102% Car 10 100% 44% Ans 10 92% 0% Cys.sub.2 50 80% 65%

(97) When the external standard solution (plasma balance amino acids mixed standard solution) of the present invention prepared in Example 1 was employed, the recovery rate of 35 kinds of compound employed as a standard product was 80 to 111%, while when the external standard solution (the conventional amino acids mixed standard solution) of Comparative Example was employed, it was 0 to 392%. That is, using the external standard solution (the conventional amino acids mixed standard solution) of Comparative Example, in the case where the calibration curve was made up using 5 calibration points in the range where lower limit concentration gave 20 time dilution of the upper limit concentration, the result was lacking in accuracy because there were many compounds whose quantitative values is outside the range of the calibration curve. In other words, it turned out that in order to make various kinds of amino acid positioned within the limits of a calibration curve using the external standard solution of Comparative Example (conventional amino acids mixed standard solution), it is necessary to increase the dilution magnification of the lower limit concentration relative to the upper limit concentration, and besides, to increase the number of calibration points (for example, at 1000 times dilution concentration, and 10 calibration points).

(98) On the other hand, it turned out that when a calibration curve was made up using the external standard solution (plasma balance amino acids mixed standard solution) of the present invention obtained in Example 1, even if it had a range where the minimum concentration was given by 20 time dilution of the maximum concentration, and even if calibration point was 5 points, the concentration of various kinds of amino acid can be measured with high accuracy because the concentration of various kinds of amino acid enters within the range of calibration curve. Therefore, it turned out that the external standard solution (plasma balance amino acids mixed standard solution) of the present invention is very useful in determination of amino acids in a biological sample.

Example 4: Quantitative Analysis of Amino Acids in the External Standard Solution Using Internal Standard Solution of the Present Invention

(99) (1) An Internal Standard Solution and an External Standard Solution of the Present Invention

(100) The internal standard solution (Example 2 in Table 5) of the present invention prepared in Example 2 was employed as an internal standard. In addition, as a comparative example, the conventional internal standard solution (Comparative Example in Table 5) prepared in Example 2 was used as an internal standard.

(101) In addition, the external standard solution (plasma balance amino acids mixed standard solution) of the present invention of the concentration 1 in Table 4 obtained in Example 1 was subjected to serial dilution in turn to give 5/4-times, 5/3-times, 2-times, 5/2-times, 10/3-times, 5-times, 10-times, 20-times, and 40-times, and 10 concentrations were prepared as amino acids for measurement.

(102) After 75 L of the internal standard solution of the present invention of Example 2 was added to 75 L of the external standard solution (plasma balance amino acids mixed standard solution) of Example 1 and mixed well, 150 L of acetonitrile was added thereto and mixed well. Similarly, after 75 L of the conventional internal standard solution of Example 2 was added to 75 L of the external standard solution (plasma balance amino acids mixed standard solution) of Example 1 and mixed well, 150 L of acetonitrile was added thereto and mixed well.

(103) (2) Precolumn Derivative

(104) With the use of 3-aminopyridyl-N-hydroxysuccinimidyl carbamate reagent, precolumn derivatization was performed. To 185 L of 200 mM borate buffer solution (pH 8.8), 10 L of the solution including the internal standard solution of the present invention of the above described (1) was added, and mixed well. Further, 5 L of 3-aminopyridyl-N-hydroxysuccinimidyl carbamate reagent (the one which was prepared by dissolving 20 mg in 1 mL of acetonitrile) was added and mixed well, then warmed at 60 C. for 5 minutes, and used it as a sample for analysis. Similarly, to 185 L of 200 mM borate buffer solution (pH 8.8), 10 L of the solution including the conventional internal standard solution of the above described (1) was added, and mixed well. Further, 5 L of 3-aminopyridyl-N-hydroxysuccinimidyl carbamate reagent was added and mixed well, then warmed at 60 C. for 5 minutes, and used this as a sample for analysis as comparative example.

(105) (3) Analysis with High Performance Liquid Chromatography-Mass Spectrometry System

(106) The above described sample for analysis was analyzed by the following conditions, respectively: High performance liquid chromatography: 20A series (Shimazu Corporation); Analytical column: Inertsil ODS-3 (GL Science Inc.); Prefilter: 0.5 m disk, for prefilter (Shimazu Corporation); Mobile phases: Mobile phases A: 25 mM formic acid (pH was adjusted to 6.0 with aqueous ammonia); Mobile phases B: Acetonitrile; Column temperature: 40 C.; Sample injection volume: 5 L; Mass spectrometer: LCMS2020 (Shimazu Corporation); Monitor ion: EtONH.sub.2: 182, Gly: 196, Ala: 210, Sar: 210, GABA: 224, -AiBA: 224, -ABA: 224, Ser: 226, Pro: 236, Val: 238, Thr: 240, Tau: 246, HyPro: 252, Ile: 252, Leu: 252, Asn: 253, Asp: 254, Gln: 267, Glu: 268, Met: 270, His: 276, -AAA: 282, Phe: 286, 1MeHis: 290, 3MeHis: 290, Arg: 295, Cit: 296, Tyr: 302, Trp: 325, Car: 347, Ans: 361, Orn: 373, Lys: 387, -HyLys: 403, Cys.sub.2: 481.

(107) After the measurement, using the measurement results, normalized response factor was calculated. That is, the response factors were calculated by dividing the peak area ratio by the concentration value, and the response factors were standardized by regarding the response factors of the concentration 8 as 1.0.

(108) The following table 7 shows the response factor obtained from the result used internal standard solution of the present invention, and Table 8 shows the response factor obtained from the result used the conventional internal standard solution. It should be noted that Table 7 and 8 indicate only about amino acids from which internal standard solution differs.

(109) It should be noted that, based on the above described results, the one, in which difference in linearity between Example and Comparative Example was observed, was given gray color in framework in the table (gray: corresponds to the concentration range from the minimum concentration to the maximum concentration of the amino acid in human plasma shown in Table 3), and aside of each abbreviation for amino acid, : difference between Example and Comparative Example was greater than 0.3 in the gray part, : the difference was 0.2 to 0.3, : the difference was 0.1 to 0.2, .box-tangle-solidup.: the difference was less than 0.1 were added, respectively. In addition, * represents the one from which the labeled element differs among those in which such a difference has been observed, and ** represents the one in which stable isotope of different amino acid is used, among those in which such a difference has been observed.

(110) TABLE-US-00009 TABLE 7 Concentration of external standard solution Amino Conc. Conc. Conc. Conc Cone. Conc. Cone. Conc. Conc. Conc. Acid 1 2 3 4 5 6 7 8 9 10 Asp 0.93 0.90 0.94 0.89 0.92 0.93 0.93 1.00 1.01 1.33 Asn .box-tangle-solidup.** 0.99 0.99 1.00 0.99 0.97+ 0.99+ 0.98+ 1.00+ 1.04 1.03 Gly * 0.93 0.95 0.96+ 0.96+ 0.97+ 0.96+ 0.98+ 1.00+ 0.98 1.01 His 0.96 0.97 0.95 0.96 0.96 0.97 0.97 1.00 0.98 1.00 Cit 0.91 0.94 0.98 0.94 0.96 0.93 0.98 1.00 1.01 1.02 Tau ** 0.83 0.85 0.89+ 0.89+ 0.91+ 0.94+ 0.98+ 1.00+ 1.14+ 1.23 Thr 0.96 0.96 0.99 0.95 0.98 0.96 0.99 1.00 1.02 1.04 Pro * 1.01+ 0.99+ 0.99+ 1.01+ 1.01+ 0.97+ 1.00+ 1.00 1.01 1.04 Tyr ** 0.98 0.99 0.99 0.99 0.98 0.99+ 1.00+ 1.00+ 0.99+ 1.00 Val * 0.98 0.97 0.97 0.97 0.96 0.97 0.99 1.00 0.99 1.01 Met * 0.97+ 0.98+ 0.99+ 0.99+ 0.99+ 0.99+ 0.98+ 1.00 0.99 1.02 Orn 1.03 1.00 1.03 0.99 1.03 0.99 1.02 1.00 1.03 1.04 Lys 0.96 0.97 0.97 0.96 0.97 1.01 0.98 1.00 1.00 0.99 Ile .box-tangle-solidup.** 0.96 0.95 0.95 0.97 0.97 0.96+ 0.98 1.00+ 0.99+ 0.99 Phe .box-tangle-solidup.** 0.96 0.97 0.98 0.97 0.97 0.97+ 0.96+ 1.00+ 0.98 0.98 Trp ** 1.01 1.00 1.00 1.00+ 1.01+ 1.00+ 1.00+ 1.00+ 1.03 1.02

(111) TABLE-US-00010 TABLE 8 Concentration of external standard solution Amino Conc. Conc. Conc. Conc. Conc. Conc. Conc. Conc. Conc. Conc. acid 1 2 3 4 5 6 7 8 9 10 Asp 0.97 1.00 0.97 0.96 0.95 0.96 0.98 1.00 1.08 1.22 Asn .box-tangle-solidup.** 0.84 0.87 0.89 0.92 0.94+ 0.98+ 0.99+ 1.00+ 1.02 1.03 Gly * 0.74 0.78 0.83+ 0.86+ 0.88+ 0.93+ 0.96+ 1.00 1.01 1.05 His 0.97 0.96 0.97 0.98 0.99 1.00 0.98 1.00 1.03 1.03 Cit 0.89 0.91 0.93 0.94 0.95 0.97 0.98 1.00 1.01 0.99 Tau ** 1.56 1.49 1.54+ 1.26+ 1.35+ 1.31+ 1.14+ 1.00+ 0.98+ 1.01 Thr 1.04 1.05 1.05 1.01 1.04 1.05 1.02 1.00 1.00 1.00 Pro * 0.46+ 0.51+ 0.57+ 0.61+ 0.67+ 0.74 0.83+ 1.00 1.08 1.11 Tvr ** 0.62 0.67 0.74 0.75 0.80 0.86+ 0.92+ 1.00+ 1.03+ 1.04 Val * 0.66 0.69 0.72 0.73 0.75+ 0.83+ 0.90+ 1.00 1.17 1.24 Met * 0.82+ 0.86+ 0.86+ 0.89+ 0.91+ 0.95+ .0.96+ 1.00 1.03 1.03 Orn 1.01 0.99 1.01 1.01 0.99 1.03 1.02 1.00 1.00 1.01 Lys 0.96 0.97 0.99 0.97 0.97 1.01 1.01 1.00 1.01 1.02 Ile .box-tangle-solidup.** 0.72 0.75 0.78 0.79 0.82 0.89+ 0.93+ 1.00+ 1.06+ 1.11 Phe .box-tangle-solidup.** 0.82 0.87 0.87 0.87 0.90 0.95+ 0.98+ 1.00+ 1.01 1.05 Try ** 1.11 1.16 1.14 1.09+ 1.11+ 1.13+ 1.08+ 1.00+ 0.95 0.94

(112) It turned out that when the internal standard solution of the present invention was employed, as compared with the conventional internal standard solution, the linearity of Asn, Gly, Tau, Pro, Tyr, Val, Met, Ile, Phe, and Trp were improved. That is, it was suggested that the internal standard solution of the present invention can give a quantitativity for wide concentration range, and it would be quite useful in determination of amino acids in a biological sample. In addition, it turned out that, in the amino acid concentration range (gray parts in the table) in human plasma, as compared with the conventional internal standard solution, the linearity has been improved particularly in Gly, Tau, Pro, Tyr, Val, Met, and Trp, and among them, the linearity has been improved especially in Tau and Pro.

(113) Other embodiment which may be derived by combining the above described each embodiment, or by adding various changes by the method well known to those skilled in the art is also included in the scope of the present invention.

INDUSTRIAL APPLICABILITY

(114) The present invention, in the quantitative analysis of amino acid in plasma, is intended to provide an external standard solution which is consistent with the existence concentration of amino acid of the object for analysis, and a method for quantitative method of amino acid using said external standard solution. Thereby, the number of calibration points for making up a calibration curve can be reduced, and also the concentration range of the amino acid of the object for analysis can be narrowed down and the quantitative analysis of the amino acid with higher accuracy become possible. Therefore, the present invention provides a significant effect as compared with the conventional technology, and is extremely useful.

REFERENCE SIGNS LIST

(115) In the FIGURE, represents the average concentration of various kinds of amino acid of 6469 specimens measured in Experimental Example 1; .diamond-solid. represents the average concentration +2 SD (standard deviation) of various kinds of amino acid measured in Experimental Example 1; .box-tangle-solidup. represents the average concentration 2 SD (standard deviation) of various kinds of amino acid measured in Experimental Example 1; represents the external standard solution (concentration 1) of the present invention prepared in Example 1; represents the external standard solution (concentration 5) of the present invention prepared in Example 1; * represents the conventional amino acids mixed standard solution (concentration 1) prepared in Comparative Example 1; and represents the conventional amino acids mixed standard solution (concentration 5) prepared in Comparative Example 1; respectively. In addition, bars prolonged up and down represent the maximum and the minimum values at the time of measuring the amino acids of 6469 specimens.